Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Everolimus in Advanced RCC
NCT02454478Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in renal cell carcinoma (RCC), sponsored by Eisai Co., Ltd. Primary endpoints: Dose Limiting Toxicity and Treatment-emergent Adverse Events. Started Jul 2015; status: completed.
02
Drugs
lenvatinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02454478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454478.